As RIL's revenue increases by 7.1% in FY25, Ambani, in RIL's FY25 annual report, highlights the company's strategic shift ...

Some high-profile healthcare names are at even cheaper valuations. For example, Merck is trading at a forward P/E of 8.7, ...

Profit-takers like Yang threaten to kill a budding upturn in Chinese industrial stocks and commodities that was triggered by ...